# Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

> **NCT03761108** · PHASE1,PHASE2 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 387 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Linvoseltamab

## Key facts

- **NCT ID:** NCT03761108
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-01-23
- **Primary completion:** 2033-03-30
- **Final completion:** 2033-06-16
- **Target enrollment:** 387 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03761108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03761108, "Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT03761108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*